Article: Elemental impurities: certified reference materials for ICH Q3D, USP<232> & <2232> and Ph.Eur. 5.20
Metallic contamination in drug products, referred to as elemental impurities, may arise from several sources.
They may be added intentionally in synthesis, or may be present as contaminants, (e.g., through interactions with processing equipment or by being present in components of the drug product) and are consequently detectable in the drug product. Since elemental impurities pose a risk to patient health due to toxicological effects, element impurity levels should be controlled within acceptable limits in the drug product.
Evolution of ICH Q3D guidelines
In 2009 the International Conference on Harmonization (ICH) proposed the development of a new harmonized guideline to provide a global policy for limiting metal impurities in drug products and ingredients.
Please read and download the full Article below:3 Elemental Impurities
Related content from this organisation
- Merck to support development of Orna’s circular RNA (oRNA) therapies
- Formulation development outsourcing market to be worth over $60bn by 2030
- Pursuing new paths in targeted protein degradation drug development
- Efficient shutdown recovery: leveraging RMM to unlock value and ensure environmental quality
- Improved outcome for prostate cancer patients in Phase III PROpel trial